- 详细信息
- 文献和实验
- 技术资料
- 物种来源:
小鼠
- 是否是肿瘤细胞:
0
- 库存:
大量
- 运输方式:
冻存运输
- 生长状态:
悬浮生长
- ATCC Number:
HB-10500™
- 免疫类型:
IgG1; kappa light chain
- 细胞形态:
淋巴样
| Designations: | T529-15D3-18-1A3-1B7 [1B7, CTCC 10752] | ||
| Depositors: | Chiron Corp. | ||
| Isotype: | IgG1; kappa light chain | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma) | ||
| Morphology: | lymphoblast |
||
| Source: | Cell Type: hybridoma: B lymphocyte; | ||
| Cellular Products: | immunoglobulin; monoclonal antibody; against the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Comments: | The hybrid hybridoma cell lines 1B7 (ATCC HB-10500 ) and 1A7 (ATCC HB-10501 ) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines. [56195 ] The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein. The murine hybridoma 3G8 recognizes the human Fc gamma receptor III. The hybrid hybridoma cell lines 1B7 and 1A7 produce bispecific antibodies that recognize both the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein. [56196 ] The 1B7 and the 1A7 antibodies are capable of binding to both the Fc receptors of cytotoxic cells, and tumor cells exhibiting multi-drug resistance phenotype, wherein the tumor cells over-express P-glycoproteins as compared to normal cells. [56196 ] These bispecific antibodies are useful in killing cancer cells. [56196 ] |
||
| Propagation: | ATCC complete growth medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 1% OPI (0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, 0.0082 mg/ml bovine insulin), 90%; heat-inactivated fetal bovine serum, 10% Temperature: 37.0°C |
||
| Subculturing: | Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
||
| Preservation: | culture medium 95%; DMSO, 5% | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005 parental cell line:ATCC HB-11342 |
||
| References: | 56193: Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000 56195: Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999 56196: Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000 |
||
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验costimulatory properties for T cells[J]. J Exp Med, 2001, 193:839-846.[17] Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity[J]. J Mol Med, 2003, 81:281-287.[18] Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially
IL-16 趋化作用 IL-18 促进Thl细胞和B细胞分泌淋巴因子,激活NK细胞 IL-21 促进NK细胞发育,刺激T细胞和B
Cytokine and Costimulatory Factor-Encoding Plasmids as Adjuvants for DNA Vaccination
The induction of a potent and long-lasting immunity is one of the most important elements to consider in developing an effective vaccine. DNA vaccines induce markedly stronger CD8+ cytotoxic T lymphocyte (CTL) activity than do traditional
技术资料暂无技术资料 索取技术资料





